Concepedia

Robert Byerly

RB

Statistics

Publications

2

Citations

52

H-Index

2

Active since

2013

Affiliations

GlaxoSmithKline (United States)(Current)

Research Triangle Park Foundation

GlaxoSmithKline (United Kingdom)

Robert Byerly is an author at GlaxoSmithKline (United States) specializing in immunology, diabetes, and cell signaling.

Top concepts

Publications per year

2013–2015

2

Publications

2

<scp>GSK256073</scp> , a selective agonist of G‐protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus

Robert L. Dobbins, Shawn Patrick Shearn, Robert Byerly et al. · Diabetes Obesity and Metabolism · 2013 · 33 citations

GSK256073 acutely regulates NEFA levels via HCA2 agonism but does not achieve durable glycaemic control in type 2 diabetes. A randomised trial

Robert L. Dobbins, Robert Byerly, Riley Gaddy et al. · European Journal of Pharmacology · 2015 · 19 citations

, , +9

1–2 of 2